Ondřej Havránek

This study identifies multiple resistance mechanisms to ETS-targeting agents in DLBCL and suggests combination therapies with BCL2, MCL1, and XPO1 inhibitors.

This study identifies PLK1 inhibition as a strategy to enhance BTK blockade in MZL by overcoming resistance through transcriptomic and mechanistic analysis.

This study investigates how PIK3CA gain and PTEN loss affect MCL biology and drug response, finding reduced BCR dependence and increased therapy resistance.

The paper identifies TCF4 overexpression driven by 18q21.2 gains as a mechanism promoting IgM expression in ABC-like DLBCL and shows BET inhibitors can suppress it.